TrialCancer research communications2025

A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers.

Andrew H Ko et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.